Evidence map›Paper›PMID 36269315›Full record

ArticleInternal medicine journal2023

Diabetes IN hospital - Glucose and Outcomes in the COVID-19 pandemic (DINGO COVID-19): the 2020 Melbourne hospital experience prior to novel variants and vaccinations.

Rahul D Barmanray, Joanna Y Gong, Mervyn Kyi, Dev Kevat, Mohammad A Islam, Anna Galligan, Georgina R Manos, Indu V Nair, Nayomi Perera, Nicholas K Adams and 11 more

Open access · hybridAbstract read
In one paragraph

Article in Internal medicine journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 1 country.

Rahul D BarmanrayDepartment of Diabetes & Endocrinology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.ORCID 0000-0002-1433-2239
Joanna Y GongDepartment of Diabetes & Endocrinology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Mervyn KyiDepartment of Diabetes & Endocrinology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.ORCID 0000-0002-4341-8250
Dev KevatDepartment of Endocrinology & Diabetes, Western Health, Melbourne, Victoria, Australia.
Mohammad A IslamDepartment of Endocrinology, Austin Health, Melbourne, Victoria, Australia.
Anna GalliganDepartment of Endocrinology & Diabetes, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
Georgina R ManosDepartment of Endocrinology & Diabetes, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
Indu V NairDepartment of Endocrinology, Northern Health, Melbourne, Victoria, Australia.
Nayomi PereraDepartment of Endocrinology & Diabetes, Western Health, Melbourne, Victoria, Australia.
Nicholas K AdamsDepartment of Endocrinology & Diabetes, Western Health, Melbourne, Victoria, Australia.
Ashvin NursingDepartment of Endocrinology & Diabetes, Western Health, Melbourne, Victoria, Australia.
Annabelle M WarrenDepartment of Endocrinology, Northern Health, Melbourne, Victoria, Australia.
Peter S HamblinDepartment of Endocrinology & Diabetes, Western Health, Melbourne, Victoria, Australia.ORCID 0000-0002-6280-865X
Richard J MacIsaacAustralian Centre for Accelerating Diabetes Innovations (ACADI), The University of Melbourne, Melbourne, Victoria, Australia.
Elif I EkinciAustralian Centre for Accelerating Diabetes Innovations (ACADI), The University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0003-2372-395X
Balasubramanian KrishnamurthyDepartment of Endocrinology & Diabetes, Western Health, Melbourne, Victoria, Australia.
Harin KarunajeewaDepartment of Medicine, Western Health, The University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0002-5786-1448
Kirsty BuisingVictorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Kumar VisvanathanDepartment of Medicine, St Vincent's Hospital, The University of Melbourne, Melbourne, Victoria, Australia.
Thomas W H KayDepartment of Medicine, St Vincent's Hospital, The University of Melbourne, Melbourne, Victoria, Australia.
Spiros FourlanosDepartment of Diabetes & Endocrinology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
The University of Melbourne · AUThe Royal Melbourne Hospital · AUWestern Health · AUNorthern Health · AUSt Vincent's Hospital Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsA relationship between diabetes, glucose and COVID-19 outcomes has been reported in international cohorts. This study aimed to assess the relationship between diabetes, hyperglycaemia and patient outcomes in those hospitalised with COVID-19 during the first year of the Victorian pandemic prior to novel variants and vaccinations. DESIGN,

settingRetrospective cohort study from March to November 2020 across five public health services in Melbourne, Australia.

participantsAll consecutive adult patients admitted to acute wards of participating institutions during the study period with a diagnosis of COVID-19, comprising a large proportion of patients from residential care facilities and following dexamethasone becoming standard-of-care. Admissions in patients without known diabetes and without inpatient glucose testing were excluded.

resultsThe DINGO COVID-19 cohort comprised 840 admissions. In 438 admissions (52%), there was no known diabetes or in-hospital hyperglycaemia, in 298 (35%) patients had known diabetes, and in 104 (12%) patients had hyperglycaemia without known diabetes. ICU admission was more common in those with diabetes (20%) and hyperglycaemia without diabetes (49%) than those with neither (11%, P < 0.001 for all comparisons). Mortality was higher in those with diabetes (24%) than those without diabetes or hyperglycaemia (16%, P = 0.02) but no difference between those with in-hospital hyperglycaemia and either of the other groups. On multivariable analysis, hyperglycaemia was associated with increased ICU admission (adjusted odds ratio (aOR) 6.7, 95% confidence interval (95% CI) 4.0-12, P < 0.001) and longer length of stay (aOR 173, 95% CI 11-2793, P < 0.001), while diabetes was associated with reduced ICU admission (aOR 0.55, 95% CI 0.33-0.94, P = 0.03). Neither diabetes nor hyperglycaemia was independently associated with in-hospital mortality.

conclusionsDuring the first year of the COVID-19 pandemic, in-hospital hyperglycaemia and known diabetes were not associated with in-hospital mortality, contrasting with published international experiences. This likely mainly relates to hyperglycaemia indicating receipt of mortality-reducing dexamethasone therapy. These differences in published experiences underscore the importance of understanding population and clinical treatment factors affecting glycaemia and COVID-19 morbidity within both local and global contexts.

Indexed as

COVID-19Diabetes MellitusHyperglycemiaAdultDexamethasoneGlucoseHospital MortalityHospitalsHumansIntensive Care UnitsPandemicsRetrospective StudiesDexamethasoneGlucose

Identifiers

PMID36269315
PMCPMC9874487
OpenAlexW4307035480

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.